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Abstract
Purpose We evaluated the relationship between bone
metastasis (BM) and clinical or pathological variables,
including the serum prostate-speciWc antigen (PSA) con-
centration.
Methods This retrospective study included 579 consecu-
tive patients with newly diagnosed prostate cancer (Pca)
who underwent a bone scan study at our institution between
2002 and 2010. We used receiver operating characteristics
curves to evaluate accuracy of bone metastasis between
serum PSA 10 and 20 ng/mL.
Results  A positive bone scan result was found in 83 men
(14.3%) with PCa. However, 27 men (4.6%) with serum
PSA between 10 and 20 ng/mL, 29/579 men (5.0%) with
GS · 7, and 21/83 (25.3%) with serum PSA · 20 ng/mL
and Gleason score (GS) · 7 had positive bone scans. In
the logistic regression analyses, clinical T stage (odds
ratio [OR] = 3.26; 95% CI, 2.29–4.33; P = 0.021), GS
(OR = 3.41; 95% CI, 2.91–4.63; P = 0.019), and serum
PSA (OR = 8.37; 95% CI, 3.91–19.21; P < 0.001) were
predictive factors of detecting the BM. When the serum
PSA concentration ·20 ng/mL and GS · 7, AUC value of
bone scans for the detection of BM was 0.640 (P = 0.020;
95% CI, 0.563–0.717). With serum PSA at 10 ng/mL and
GS · 7, the AUC values of bone scans were 0.828
(P < 0.001; 95% CI, 0.773–0.883).
Conclusions Bone scans might be necessary in men with
serum PSA between 10 and 20 ng/mL. New guidelines for
eliminating bone scans in patients with newly diagnosed
Pca are needed, especially in Asians.
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Introduction
Considering that the most frequent site of metastatic pros-
tate carcinoma is bone [1], detection of bone metastasis is
important when deciding the treatment strategy of prostate
cancer. Bone scanning is the most sensitive modality for
the detection of bone metastasis but it is also an expensive
and time-consuming staging modality [2]. Therefore, it is
important to seek a balance between cost and beneWt.
According to the American Urologic Association (AUA)
and European Association of Urology (EAU) guidelines,
scanning may not be necessary for those with serum pros-
tate-speciWc antigen (PSA) · 20 ng/mL when they have
Gleason score (GS) · 7 [3, 4]. These guidelines are reX-
ected in the clinical guidelines for prostate cancer published
by the Japanese Urological Association in 2006 [5].
However, it has not been suYciently investigated
whether this standard is suitable for Asians with relatively
small prostates in size or lower serum PSA levels [6, 7]. In
Japan, a multicenter retrospective study suggests the inci-
dence of positive bone scanning in patients with low PSA
levels is much higher than that in other studies conducted in
North America and Europe [8]. According to mass popula-
tion screening in Korea, the distribution of serum PSA val-
ues in Koreans was diVerent from that obtained in
Caucasians [9].
Therefore, we evaluated the relationship between bone
metastasis and clinical or pathological variables, including
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tried to determine the clinical proWles of patients for whom
bone scanning could be eliminated due to a low probability
of bone metastasis.
Methods
This retrospective study included 579 consecutive patients
who were newly diagnosed with adenocarcinoma of the pros-
tate and underwent a bone scan study at our single tertiary
referral institution between 2002 and July 2010. They all had
transrectal ultrasound (TRUS) guided prostate biopsies,
serum PSA levels, and bone scans within 3 months of one
another. We excluded patients who had a history of 5-alpha-
reductase inhibitors treatment for benign prostatic hyper-
plasia or that of other malignant diseases with possible
development of BM. All prostate biopsies were performed
using a standard 18-gauge biopsy gun, and the number of
biopsy sites ranged from six to ten with additional targeted
biopsies for any hypoechoic or suspicious lesion. For each
needle biopsy, certain variables were assessed, including GS,
the percentage of tumor as a function of all the biopsy tis-
sues, the number of cancer-positive cores, and the total num-
ber of cores from all biopsy sites. The serum PSA level was
determined by the Hybritech, Tosoh, or Abbot assay with the
normal range set between 0 and 4.0 ng/mL.
Bone scintigrams were performed with technetium-99m
HDP. The dose of Tc-99m HDP used was approximately
20 mCi (740 MBq), and scanning was performed by a sin-
gle head—camera high-resolution collimator was used, and
whole body anterior and posterior planner images, together
with oblique and localized views for areas of interest, were
reviewed. The bone scintigrams were reviewed by two
experienced radiologists with knowledge of PSA, biopsy
GS, and digital rectal examination Wndings. Patients with
unclear bone scan Wndings underwent additional computed
tomography and/or magnetic resonance imaging to conWrm
the bone scan Wndings. To evaluate accuracy of bone metasta-
sis with serum PSA · 20 ng/mL or serum PSA · 10 ng/mL,
the receiver operating characteristics (ROC) curve analysis
derived area under the curve (AUC) estimates determined
the cutoV points of each predictor, and then their sensitiv-
ity, speciWcity, and positive predictive value (PPV) were
analyzed. The SPSS version 17.0 (SPSS Inc., Chicago,
IL, USA) for Windows was used for statistical analysis,
and a probability (P) level of <0.05 was considered
signiWcant.
Results
Eighty-three patients (14.3%) had a positive bone scan.
Median age of patients with and without bone metastasis
was 74 and 68 years old, respectively (P = 0. 027).
The median PSA and biopsy GS were 49.6 ng/mL and 7.4,
respectively, in patients with bone metastasis and 7.3 ng/mL
and 6.4 in those without bone metastasis (Table 1).
Of 58 patients with bone pain, 49 (82.8%) had bone
metastasis. Positive bone scans were obtained from 27
patients (4.5%) with a serum PSA between 10 and 20 ng/mL,
one (0.2%) with serum PSA below 10 ng/mL, and 55
(9.5%) with serum PSA above 20 ng/mL. Of 29 patients
with bone metastasis who had GS below 7, 1 (1.2%),
9 (10.8%), 19 (22.9%) patients were found in GS 5, 6, 7,
respectively, (Fig 1). Of 83 patients with bone metastasis,
21 (25.3%) with a serum PSA · 20 ng/mL and GS · 7. In
the logistic regression analyses, clinical T stage (odds
ratio = 3.26; 95% CI, 2.29–4.33; P = 0.021), GS
(OR = 3.41; 95% CI, 2.91–4.63; P = 0.019), and serum
PSA (OR = 8.37; 95% CI, 3.91–19.21; P < 0.001) were the
predictive factor detecting BM (data not shown).
With the serum PSA concentration ·20 ng/mL and
GS · 7, the mean sensitivity was 74.7%, speciWcity 92.9%
(Table 2), and the AUC value of bone scans for the detec-
tion of BM 0.640 (P = 0.020; 95% CI, 0.563–0.717)
(Fig. 2). With the serum PSA at 10 ng/mL and GS · 7, the
mean sensitivity was 98.4%, speciWcity 83.9%, and the
AUC values of bone scans 0.828 (P < 0.001; 95% CI,
0.773–0.883) (Fig. 2).
Table 1 Patient characteristics 
and clinical stage at diagnosis Clinical variables Bone metastasis (+) Bone metastasis (¡) P value
No. of patients 83 496
Median age (years) 74 (53–89) 68 (46–87) 0.027
Median PSA (ng/mL)* 49.6 (7.9–1221.5) 7.3 (3.6–54.3) <0.001
Biopsy Gleason score (mean)* 7.4 § 0.8 6.4 § 0.5 0.031
Clinical stage** <0.001
T1–2 5 (6.0%) 393 (79.2%)
T3 41 (49.4%) 84 (16.9%)
T4 37 (44.6%) 19 (3.8%)
* <0.05 by student’s t test
** <0.05 by Pearson chi-square 
test123
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We observed bone metastasis in 14.3% of newly diag-
nosed Pca, which is higher than that in the United States
(8.9%) [10]. and lower than that in Japan (22.2%) [8].
Recently, the epidemiology of prostate cancer in the
Asian population has changed, thanks to the increasing
awareness of the disease entity, the advent of the PSA
testing for screening, and the increase in life expectancy
of the male population [11]. In South Korea, the inci-
dence of prostate cancer is rapidly increasing, ranking
Wfth among the most common cancers in the male popu-
lation in 2007 [12]. Therefore, our lower incidence of
metastatic Pca compared to previous Asian studies [8,
13] might be due to the increasing awareness of PSA
screening in Korea.
In our study, 83 men had a positive bone scan. Among
them, 21 patients (25.3%) had serum PSA · 20 ng/mL and
GS · 7 at the time of the diagnosis. The aim of bone scan is
to detect occult locoregionally advanced or distant meta-
static disease that would alter the primary treatment plan.
ConWning the bone scan analysis to less strict criteria would
have increased the sensitivity but decreased positive predic-
tive ability. However, what is important when determining
Fig. 1 Percentage of bone metastasis according to baseline symptom, PSA, and biopsy Gleason scores
Table 2 Comparison of diagnostic accuracy for assessment of bone
metastasis according to PSA levels
PSA prostate-speciWc antigen, GS Gleason scores, PPV positive
predictive value, NPV negative predictive value
PSA · 20 
and GS · 7
PSA · 10 
and GS · 7
Sensitivity (%) 74.7 98.8
SpeciWcity (%) 92.9 84.3
PPV (%) 63.9 51.3
NPV (%) 95.6 99.8
Fig. 2 Receiver operant characteristic curve for data obtained from
patients with PSA · 20, Gleason score · 7 (a) and PSA · 10, Glea-
son score · 7 (b) with bone metastasis correlation123
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impact our decision to recommend patients for prostatec-
tomy. By applying the EAU or AUA guideline [3, 4], 3.6%
(21/579) patients in our study would have not been detected
with bone metastasis at proper time. Recently, Briganti
et al. [14] suggested that staging bone scans might be con-
sidered only for patients with a biopsy GS > 7 or with
PSA > 10 ng/mL and palpable disease (cT2/T3) prior to
treatment (AUC range: 88.0%; P < 0.002). Similarly, AUC
increased from 0.640 with PSA > 20 ng/mL to 0.828 with
PSA > 10 ng/mL. These results suggest that skeletal
screening may be required even for patients with a serum
PSA level between 10 and 20 ng/mL.
In contrast to other studies conducted in Western coun-
tries, a multi-center retrospective study conducted in Japan
revealed that bone metastasis was common in Japanese
patients with newly diagnosed untreated prostate carcinoma
with an overall positive rate of 22.2% on bone scans [8].
Moreover, Ito et al. [15] found 303 patients with CaP and
36 with bone metastasis among 9,671 patients. Among
those with bone metastasis, 13 patients (36%) had PSA lev-
els of 10 ng/mL or less. The incidence of positive bone scan
in a patient group with low PSA levels is much higher than
the other studies in the Western countries. In a Hong Kong
study, Lai et al. [11] recommend omitting bone scan if
serum PSA is 10 ng/mL or less. If imaging had been denied
only to patients with a PSA level of 20 ng/mL or less, imag-
ing sensitivity would have decreased to 94%.
Our data are inconsistent when applied to AUA or
EAU guideline. Our results might be due to more aggres-
sive and poorly diVerentiated PCa in Korean men,
despite a low clinical stage or low serum PSA level [16].
In another report, twice as many Asian men had a GS of
8 or greater, the worst stage at presentation, and were,
accordingly, classiWed as being at high risk, as compared
with non-Asian men [17]. PSA expression is strongly
inXuenced by androgens [18]. Thus, hypogonadal men
with low testosterone levels may show low serum PSA
levels because of decreased expression, and their serum
PSA may not reXect the presence of prostate disease
such as cancer [19]. Asian males tend to have lower total
serum testosterone and hormone-binding levels, a reduc-
tion in 5-alpha-reductase levels, and lower testosterone
production rates compared with white men [20]. A pre-
vious investigation involving a large number of healthy
Japanese [6], Chinese [21], and Korean [9] men showed
a lower median value of serum PSA for Asian men than
that for Caucasians.
This study has several limitations. First, this is a retro-
spective study. Second, we could not conWrm the histology
of the bone metastasis detected by bone scans. Even though
bone scintigraphy is accurate and highly sensitive, there
might be a margin of error.
Conclusions
Based on our Wndings, bone scans might be necessary in
men with a serum PSA between 10 and 20 ng/mL. DiVerent
guidelines for eliminating bone scans in patients with
newly diagnosed prostate cancer are needed, especially in
Asians.
ConXict of interest There is no conXict of interest.
Open Access This article is distributed under the terms of the Cre-
ative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer
metastasis to bone. Nat Rev Cancer 5:21–28
2. Gerber G, Chodak GW (1991) Assessment of value of routine
bone scans in patients with newly diagnosed prostate cancer. Urol-
ogy 37:418–422
3. American Urological Association (AUA) (2000) Prostate-speciWc
antigen (PSA) best practice policy. Oncology (Williston Park)
14:267
4. Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on
prostate cancer. Eur Urol 53:68–80
5. Kamidono S, Ohshima S, Hirao Y et al (2008) Evidence-based
clinical practice guidelines for prostate cancer (Summary—JUA
2006 Edition). Int J Urol 15:1–18
6. Oesterling JE, Kumamoto Y, Tsukamoto T et al (1995) Serum
prostate-speciWc antigen in a community-based population of
healthy Japanese men: lower values than for similarly aged white
men. Br J Urol 75:347–353
7. Masumori N, Tsukamoto T, Kumamoto Y et al (1996) Japanese
men have smaller prostate volumes but comparable urinary Xow
rates relative to American men: results of community based stud-
ies in 2 countries. J Urol 155:1324–1327
8. Kosuda S, Yoshimura I, Aizawa T et al (2002) Can initial prostate
speciWc antigen determinations eliminate the need for bone scans
in patients with newly diagnosed prostate carcinoma? A multicen-
ter retrospective study in Japan. Cancer 94:964–972
9. Lee SE, Kwak C, Park MS et al (2000) Ethnic diVerences in the
age-related distribution of serum prostate-speciWc antigen values: a
study in a healthy Korean male population. Urology 56:1007–1010
10. Lin K, Szabo Z, Chin BB et al (1999) The value of a baseline bone
scan in patients with newly diagnosed prostate cancer. Clin Nucl
Med 24:579–582
11. Lai MH, Luk WH, Chan JC (2011) Predicting bone scan Wndings
using sPSA in patients newly diagnosed of prostate cancer: feasi-
bility in Asian population. Urol Oncol (in press)
12. Jung KW, Park S, Kong HJ et al (2010) Cancer statistics in Korea:
incidence, mortality and survival in 2006–2007. J Korean Med Sci
25:1113–1121
13. Al-Ghazo MA, Ghalayini IF, Al-Azab RS et al (2010) Do all
patients with newly diagnosed prostate cancer need staging radio-
nuclide bone scan? A retrospective study. Int Braz J Urol 36:685–
691 (discussion 691–692)
14. Briganti A, Passoni N, Ferrari M et al (2010) When to perform
bone scan in patients with newly diagnosed prostate cancer: exter-
nal validation of the currently available guidelines and proposal of
a novel risk stratiWcation tool. Eur Urol 57:551–558123
World J Urol (2012) 30:265–269 26915. Ito K, Kubota Y, Suzuki K et al (2000) Correlation of prostate-spe-
ciWc antigen before prostate cancer detection and clinicopatho-
logic features: evaluation of mass screening populations. Urology
55:705–709
16. Song C, Ro JY, Lee MS et al (2006) Prostate cancer in Korean
men exhibits poor diVerentiation and is adversely related to prog-
nosis after radical prostatectomy. Urology 68:820–824
17. Man A, Pickles T, Chi KN (2003) Asian race and impact on out-
comes after radical radiotherapy for localized prostate cancer.
J Urol 170:901–904
18. Young CY, Montgomery BT, Andrews PE et al (1991) Hormonal
regulation of prostate-speciWc antigen messenger RNA in human
prostatic adenocarcinoma cell line LNCaP. Cancer Res 51:3748–
3752
19. Morgentaler A, Bruning CO 3rd, DeWolf WC (1996) Occult pros-
tate cancer in men with low serum testosterone levels. JAMA
276:1904–1906
20. van Houten ME, Gooren LJ (2000) DiVerences in reproductive
endocrinology between Asian men and Caucasian men—a litera-
ture review. Asian J Androl 2:13–20
21. He D, Wang M, Chen X et al (2004) Ethnic diVerences in distribu-
tion of serum prostate-speciWc antigen: a study in a healthy
Chinese male population. Urology 63:722–726123
